We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Akebia Therapeutics (AKBA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Akebia Therapeutics is a member of the Medical sector. This group includes 986 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Akebia Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AKBA's full-year earnings has moved 65.4% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AKBA has returned about 104.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.7%. This means that Akebia Therapeutics is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is ResMed (RMD - Free Report) . The stock has returned 10.2% year-to-date.
For ResMed, the consensus EPS estimate for the current year has increased 1.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Akebia Therapeutics is a member of the Medical - Drugs industry, which includes 155 individual companies and currently sits at #96 in the Zacks Industry Rank. On average, stocks in this group have gained 4.1% this year, meaning that AKBA is performing better in terms of year-to-date returns.
In contrast, ResMed falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #166. Since the beginning of the year, the industry has moved +4.8%.
Investors with an interest in Medical stocks should continue to track Akebia Therapeutics and ResMed. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Akebia Therapeutics (AKBA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Akebia Therapeutics is a member of the Medical sector. This group includes 986 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Akebia Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AKBA's full-year earnings has moved 65.4% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AKBA has returned about 104.2% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.7%. This means that Akebia Therapeutics is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is ResMed (RMD - Free Report) . The stock has returned 10.2% year-to-date.
For ResMed, the consensus EPS estimate for the current year has increased 1.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Akebia Therapeutics is a member of the Medical - Drugs industry, which includes 155 individual companies and currently sits at #96 in the Zacks Industry Rank. On average, stocks in this group have gained 4.1% this year, meaning that AKBA is performing better in terms of year-to-date returns.
In contrast, ResMed falls under the Medical - Products industry. Currently, this industry has 84 stocks and is ranked #166. Since the beginning of the year, the industry has moved +4.8%.
Investors with an interest in Medical stocks should continue to track Akebia Therapeutics and ResMed. These stocks will be looking to continue their solid performance.